Surolan, an effective treatment for common and recurring cases of otitis externa in canines, has recently been approved by the Food and Drug Administration, according to Vetoquinol USA and Janssen Animal Health. The companies teamed up to offer Surolan as a unique treatment for the inflammation of the external ear canal or common aural infection. The condition impacts up to 20 percent of dogs in the United States. The most unique aspect of the Surolan formula, according to the companies, is its distinctive combination of antibiotic, anti-fungal and anti-inflammatory agents, including polymyxin B, miconazole and prednisolone. Studies show there is a synergistic effect between polymyxin B and miconazole. There is a 100 percent decrease in the concentration of medication needed to treat certain bacteria when these are used together. This synergy gives Surolan broad effectiveness against the pathogens that cause otitis externa and make it less likely to develop resistance issues. “U.S. veterinarians can prescribe Surolan as first line treatment for canine otitis externa with great confidence because of its novel formulation featuring the trial-proven synergistic action of miconazole and polymyxin B,” said Eddy Thomas, director trade worldwide for Janssen Animal Health. Surolan, formulated as a suspension, is dispensed as drops to provide a rapid, penetrating action. Additionally, it can be administered more comfortably and precisely to infected ears because it is stable and fluid at room temperature. The product should be used twice daily for seven consecutive days. Surolan does not discolor the skin or hair and causes no irritation or toxic effects when applied topically. Vétoquinol USA’s agreement with Janssen Animal Health is for the U.S. market only. There are no plans at this time to introduce Surolan beyond the U.S. Click here for more information or call 800.267.5707. <HOME>
